Generic Name and Formulations:
Carisoprodol 350mg; tabs.
Mylan Specialty L.P.
Indications for SOMA:
Relief of acute, painful musculoskeletal conditions.
≥16yrs: 250mg–350mg 3 times daily and at bedtime. Max 2–3 weeks.
<16yrs: not recommended.
Renal or hepatic dysfunction. Drug abuse. Pregnancy (Cat.C). Nursing mothers.
Sedative effects potentiated by alcohol, other CNS depressants. May be potentiated by CYP2C19 inhibitors (eg, omeprazole, fluvoxamine). May be antagonized by CYP2C19 inducers (eg, rifampin, St. John's Wort).
Muscle relaxant (central).
Dizziness, drowsiness, headache, GI upset, rash, tachycardia, orthostatic hypotension; rare idiosyncratic reactions (see literature).
Endocrinology Advisor Articles
- Efficacy and Safety of Alirocumab in Diabetes Mellitus
- Safety of DPP-IV Inhibitor, Cardiovascular Events After ACS in Type 2 Diabetes
- Adjunctive Metformin for Insulin Resistance in T1D: A Clinical Perspective
- Effect of Fructose, Allulose on Postprandial Glucose Regulation in Type 2 Diabetes
- Sex Hormone Levels May Affect Postmenopausal Heart Disease Risk
- Diabetes Treatments
- Metformin May Decrease Colorectal Cancer Risk Among Males With Diabetes
- SGLT2 Inhibitor, GLP-1 Receptor Agonist Combination Treatment for Type 2 Diabetes: Expert Insights
- Semaglutide May Induce Weight Loss in Type 2 Diabetes Despite BMI
- FDA Clears Omnipod DASH System for Diabetes Management
- Menopausal Hormone Therapy Slows Cognitive Decline in Postmenopausal Women
- Does Maintenance of Certification Status Affect Patient Care?
- Emotional Hyper-Reactivity and Cardiometabolic Risk in Remitted Bipolar Disorder
- Reduced Mortality for Women Undergoing Assisted Reproduction Likely Due to "Healthy Patient Effect"
- Romosozumab Followed by Denosumab Effective for BMD Increase in Postmenopausal Women